{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:05:53Z","timestamp":1789185953724,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.dadr.2026.100476","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:59:21Z","timestamp":1788566361000},"page":"100476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-1184","authenticated-orcid":false,"given":"Sadia","family":"Jehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen D.","family":"Seay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dadr.2026.100476_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017-21","volume":"42","author":"Andraka-Christou","year":"2023","journal-title":"Health Aff."},{"issue":"3","key":"10.1016\/j.dadr.2026.100476_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/29767342241303583","article-title":"Examining the impact of eliminating the x waiver on buprenorphine dispensation in 63 counties in pennsylvania","volume":"46","author":"Bilden","year":"2025","journal-title":"Subst. Use & Addict. J."},{"key":"10.1016\/j.dadr.2026.100476_bib3","unstructured":"CDC WONDER. (2026). Multiple Causes of Death, 2019-2023 [Dataset]. https:\/\/wonder.cdc.gov\/mcd.html"},{"issue":"16","key":"10.1016\/j.dadr.2026.100476_bib4","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"New. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.dadr.2026.100476_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","article-title":"Racial-ethnic disparities of buprenorphine and vivitrol receipt in medicaid","volume":"63","author":"Dunphy","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.dadr.2026.100476_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.029","article-title":"U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018","volume":"204","author":"Ghertner","year":"2019","journal-title":"Drug. Alcohol. Depend."},{"key":"10.1016\/j.dadr.2026.100476_bib7","article-title":"Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: a pharmacy data claims analysis from 2009-2018","volume":"9","author":"Golan","year":"2023","journal-title":"Drug. Alcohol. Depend. Rep."},{"issue":"1","key":"10.1016\/j.dadr.2026.100476_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13011-022-00457-3","article-title":"Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes","volume":"17","author":"Hirchak","year":"2022","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"issue":"2","key":"10.1016\/j.dadr.2026.100476_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s40615-021-01006-7","article-title":"Racial\/ethnic heterogeneity and rural-urban disparity of COVID-19 case fatality ratio in the USA: a negative binomial and GIS-based analysis","volume":"9","author":"Iyanda","year":"2022","journal-title":"J. Racial Ethn. Health Disparities"},{"issue":"7","key":"10.1016\/j.dadr.2026.100476_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.7326\/M19-2403","article-title":"Growth and distribution of buprenorphine-waivered providers in the United States, 2007\u20132017","volume":"172","author":"McBain","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2026.100476_bib11","unstructured":"Missouri Census Data Center. (2018). Geocorr 18. https:\/\/mcdc.missouri.edu\/applications\/geocorr2022.html"},{"issue":"4","key":"10.1016\/j.dadr.2026.100476_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215016","article-title":"Geographic variation in spatial accessibility of U.S. healthcare providers","volume":"14","author":"Naylor","year":"2019","journal-title":"PloS. One"},{"issue":"3","key":"10.1016\/j.dadr.2026.100476_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.sapharm.2023.12.001","article-title":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? a systematic review and meta-analysis","volume":"20","author":"Nedjat","year":"2024","journal-title":"Res. Social. & Adm. Pharm. RSAP"},{"issue":"3","key":"10.1016\/j.dadr.2026.100476_bib14","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/ADM.0000000000000911","article-title":"Opting into the Public List of DATA-tistics","volume":"16","author":"Nguyen","year":"2022","journal-title":"J. Addict. Med."},{"issue":"2","key":"10.1016\/j.dadr.2026.100476_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/29767342251392342","article-title":"Expanding access to buprenorphine and methadone: global perspectives and policy recommendations","volume":"47","author":"Nunes","year":"2026","journal-title":"Subst. Use & Addict. J."},{"issue":"2","key":"10.1016\/j.dadr.2026.100476_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.juro.2008.10.034","article-title":"Geographic distribution of urologists throughout the United States using a county level approach","volume":"181","author":"Odisho","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.dadr.2026.100476_bib17","unstructured":"SAMHSA. (2025). Buprenorphine Practitioner Locator [Dataset]. Retrieved February 22, 2025, from https:\/\/www.samhsa.gov\/medication-assisted-treatment\/find-treatment\/treatment-practitioner-locator"},{"key":"10.1016\/j.dadr.2026.100476_bib18","series-title":"Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration","article-title":"Key substance use and mental health indicators in the United States: Results from the 2025 National Survey on Drug Use and Health (HHS Publication No. PEP26- 07-010, NSDUH Series H-61)","author":"SAMHSA","year":"2026"},{"issue":"6","key":"10.1016\/j.dadr.2026.100476_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.dadr.2026.100476_bib20","article-title":"State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements","volume":"7","author":"Silwal","year":"2023","journal-title":"Drug. Alcohol. Depend. Rep."},{"issue":"5","key":"10.1016\/j.dadr.2026.100476_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2025.108055","article-title":"Buprenorphine dispensation after x-waiver elimination by clinician specialty","volume":"69","author":"Stone","year":"2025","journal-title":"Am. J. Prev. Med."},{"issue":"3","key":"10.1016\/j.dadr.2026.100476_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.13.3.21","article-title":"Insights into eye care accessibility: geospatial distribution of eye care providers and socioeconomic factors by ZIP Code","volume":"13","author":"Tran","year":"2024","journal-title":"Transl. Vision. Sci. & Technol."},{"key":"10.1016\/j.dadr.2026.100476_bib23","series-title":"ZIP Code Tabulation Areas (ZCTAs)","author":"U.S. Census Bureau","year":"2023"},{"key":"10.1016\/j.dadr.2026.100476_bib24","author":"U.S. Census Bureau","year":"2025","journal-title":"Am. Community Surv. Data"},{"issue":"1","key":"10.1016\/j.dadr.2026.100476_bib25","article-title":"Assessing buprenorphine treatment utilization and SAMHSA DATA waiver provider distribution in 2021: A real-world analysis in California","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.dadr.2026.100476_bib26","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1186\/s12889-025-24541-y","article-title":"Global burden, socioeconomic disparities, and spatiotemporal dynamics of opioid use disorder mortality and disability: a comprehensive analysis from the global burden of disease study 2017-2021","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Public. Health"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724626000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:13:13Z","timestamp":1789182793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724626000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S2772724626000697"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100476","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2026.100476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100476"}}